Safety and efficacy of intramedullary injection of tranexamic acid in closed reduction intramedullary nailing of long bone fractures of the lower extremities

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051947

Enrollment

Unknown

Registered

2021-10-09

Start date

2021-10-31

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fracture of femur and tibia

Interventions

Experimental group 1:Intravenous tranexamic acid + medullary tranexamic acid

Experimental group 2:Intravenous tranexamic acid + medullary normal saline

Control group:Tranexamic acid is not used at the time of admission or at the time of surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unilateral lower extremity diaphyseal fractures (tibia, femur) to be treated with closed reduction intramedullary nailing.

Exclusion criteria

Exclusion criteria: 1.Multiple trauma or fracture; 2.Open, pathological fractures or periprosthetic fractures; 3.Clearly allergic or contraindicated to tranexamic acid; 4.Abnormal platelet and coagulation function; 5.Patients with lower extremity deep venous thrombosis (intermuscular venous thrombosis and deep venous thrombosis) before surgery.

Design outcomes

Primary

Measure	Time frame
Deep Vein Thrombosis;Total blood loss;Hidden blood loss;Blood transfusion volume;Hemoglobin;Packed cell volume;	—

Countries

China

Contacts

Public ContactXiao Cong

The Third Hospital of Mianyang

syygekxc@126.com+86 13890459183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026